Suda Pharmaceuticals (ASX:SUD)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Suda Pharmaceuticals.
RELATED STOCKHEAD STORIES
Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
ScoPo’s Powerplays: Buying opportunities in a volatile week
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites
ASX Small Cap Lunch Wrap: Who’s digesting the news today?
Weed Week: Major shifts in US legislation set to open the door for some ASX cannabis stocks
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play
Rise and Shine: What you need to know before the ASX opens
Dr Boreham’s Crucible: Is Suda back on track after securing first TGA approval?
World-renown cancer institute to investigate Kazia Therapeutics drug
10 at 10: These ASX stocks are vying for silverware this morning
StockTalk: Drug delivery tech offers patients, investors massive upside
